Arcus Biosciences (RCUS) Total Liabilities (2017 - 2026)

Arcus Biosciences' Total Liabilities history runs 10 years deep, the most recent figure standing at $997.0 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 16.92% year-over-year to $997.0 million; the TTM figure through Mar 2026 stood at $997.0 million (down 16.92% YoY), while the FY2025 annual figure was $1.1 billion, down 0.96% from the prior year.
• Total Liabilities for Q1 2026 stood at $997.0 million, down from $1.1 billion in the prior quarter.
• The five-year high for Total Liabilities was $1.3 billion in Q4 2022, with the low at $695.1 million in Q3 2022.
• The 5-year median for Total Liabilities is $1.2 billion (2024), against an average of $1.1 billion.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 176.27% in 2022, then decreased 25.08% in 2025.
• Arcus Biosciences' Total Liabilities stood at $1.3 billion in 2022, then dropped by 15.77% to $1.1 billion in 2023, then rose by 5.02% to $1.2 billion in 2024, then declined by 0.96% to $1.1 billion in 2025, then slipped by 12.47% to $997.0 million in 2026.
• Business Quant data shows RCUS's Total Liabilities at $997.0 million in Q1 2026, $1.1 billion in Q4 2025, and $974.0 million in Q3 2025.